Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. WAT
WAT logo

WAT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Waters Corp (WAT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
355.440
1 Day change
-0.44%
52 Week Range
414.150
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Waters Corp (WAT) does not present a strong buying opportunity at this time for a beginner investor with a long-term strategy. While there are some positive indicators, such as Congress trading data showing a significant purchase and analysts raising price targets, the technical indicators, hedge fund selling trends, and lack of strong proprietary trading signals suggest a cautious approach. The stock's current price trend and lack of immediate catalysts do not align with the user's impatience and unwillingness to wait for optimal entry points.

Technical Analysis

The MACD is negative and expanding (-2.796), indicating bearish momentum. RSI is neutral at 39.619, and moving averages are converging, showing no clear direction. The stock is trading below the pivot level (363.395) and closer to the first support level (353.562), suggesting potential downside risk.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The Open Interest Put-Call Ratio of 0.68 and Option Volume Put-Call Ratio of 0.92 indicate a slightly bullish sentiment but not strong enough to suggest a decisive trading opportunity.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
7

Positive Catalysts

  • Congress trading data shows a significant purchase in the last 90 days, with a median amount of $3.3M.

  • Analysts have raised price targets recently, with HSBC and Wolfe Research providing optimistic outlooks.

  • The stock is part of the life sciences tools sector, which has potential for recovery according to analysts.

Neutral/Negative Catalysts

  • Hedge funds are selling, with a 125.80% increase in selling activity last quarter.

  • Technical indicators show bearish momentum and no clear upward trend.

  • Lack of recent news or event-driven catalysts to drive immediate price action.

Financial Performance

No financial data available for the latest quarter, making it difficult to assess growth trends or recent performance.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is mixed. Recent ratings include Neutral from Piper Sandler and BofA, while HSBC and Wolfe Research are more optimistic with Buy and Outperform ratings. Price targets range from $345 to $435, with a general upward adjustment reflecting improved sentiment in the life sciences tools sector.

Wall Street analysts forecast WAT stock price to rise
13 Analyst Rating
Wall Street analysts forecast WAT stock price to rise
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 357.000
sliders
Low
350
Averages
414.08
High
480
Current: 357.000
sliders
Low
350
Averages
414.08
High
480
Piper Sandler
Neutral
initiated
$400
AI Analysis
2026-06-11
Reason
Piper Sandler
Price Target
$400
AI Analysis
2026-06-11
initiated
Neutral
Reason
Piper Sandler initiated coverage of Waters with a Neutral rating and $400 price target. The firm launched coverage of the life science tools sector with a \"feet in the shallow end of the pool\" approach. Piper only recommends buying Twist Bioscience for its growing exposure to next generation drug discovery and development. Headwinds for the group faces from biotech and academic spending as well as China exposure will likely improve near term, the analyst tells investors in a research note. However, Piper wants to see some of the next big growth drivers materialize before recommending more of the stocks. Investors \"can buy multi-year growth compounding stocks early, middle, and late into their growth cycles but would simply prefer to wait out a couple quarters for the sector to perform like it did pre-Covid,\" the firm contends.
HSBC
Buy
maintain
$415 -> $435
2026-06-03
Reason
HSBC
Price Target
$415 -> $435
2026-06-03
maintain
Buy
Reason
HSBC raised the firm's price target on Waters to $435 from $415 and keeps a Buy rating on the shares. The firm says market expectations on life science tools "remain bearish" with allocation tilted towards managed care and therapeutics within healthcare. While the tools sector is priced for disappointment, HSBC sees "green shoots of recovery," notably in bioprocessing and quality assurance, the analyst tells investors in a research note. The firm adjusted target prices to reflect risk-adjusted return expectations. HSBC's preferred ideas are Waters, Iqvia, and Sartorius.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for WAT
Unlock Now

People Also Watch